The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.
You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.
We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.
We are interested in where in or outside the cell the gene product carries out its function.
We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.
Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.
Identity verified. The specified human UniProt accession P11836 corresponds to the protein CD20, encoded by MS4A1, not to another MS4A-family member. CD20 is a four-pass cell-surface protein of the MS4A family; its experimentally resolved topology agrees with the supplied CD20-like transmembrane, MS4A and CD20 domain annotations. The best-supported physiological annotation is an organizer of B-cell plasma-membrane receptor nanodomains that helps maintain the resting state and controls access to B-cell receptor (BCR) signaling. It has no established catalytic reaction, transported substrate or identified physiological ligand. Although it affects calcium responses, its proposed function as an intrinsic calcium-conducting pore remains unproven. UniProt P11836; Kläsener et al., PNAS, 9 February 2021; Rougé et al., Science, 2020. (pavlasova2020theregulationand pages 2-4, klasener2021cd20asa pages 1-2, rouge2020structureofcd20 pages 1-2, rouge2020structureofcd20 pages 4-5)
CD20 functions principally in the plasma membrane of developing and mature B lymphocytes, appearing from the late pre-B stage and generally disappearing as cells terminally differentiate into antibody-secreting plasmablasts and plasma cells. Its four membrane-spanning helices place both termini in the cytosol and two loops outside the cell, making the larger extracellular loop accessible to therapeutic antibodies. A 2020 cryo-electron microscopy study resolved antibody-bound human CD20 at 3.3 Å as a tightly packed dimer of four-helix subunits; purified CD20 bound two rituximab Fab fragments per dimer, whereas obinutuzumab Fab bound at a 1:2 Fab:CD20 ratio. Oligomeric states and associated proteins may vary in native membranes, so the isolated antibody-bound structure should not be taken to describe every cellular assembly. Pavlasova and Mraz, Haematologica, June 2020; Rougé et al., Science, 2020. (pavlasova2020theregulationand pages 2-4, rouge2020structureofcd20 pages 2-3)
The inspected structural Figure 2 shows the closely packed four-helix subunits and dimer interface; neither presents an obvious central transmembrane pore. This is structural evidence against the particular pore configurations observed, rather than proof that CD20 cannot regulate a separate channel or adopt another conformation. Rougé et al., Science, 2020. (rouge2020structureofcd20 pages 2-3, rouge2020structureofcd20 pages 4-5, rouge2020structureofcd20 media 6925c4b6)
In resting human B cells, the IgM- and IgD-class BCRs occupy distinct membrane nanodomains. Proximity assays placed CD20 near the IgD-BCR-associated compartment, together with a CD19/CD81 module and other surface proteins; after experimental activation, its proximity shifted toward IgM-BCR. In human Ramos B cells, CRISPR deletion of MS4A1 increased IgM-BCR proximity to the CD19 coreceptor, phosphorylation of SYK and AKT, and expression of activation markers CD69 and CD86. Loss of either CD19 or the BCR modified the CD20-knockout phenotype, while conditional CD20 re-expression restored surface markers and the resting phenotype. These perturbation-and-rescue results support a gatekeeper role: CD20 helps preserve an IgD-associated membrane organization that restrains inappropriate IgM-BCR/CD19 signaling. Kläsener et al., PNAS, 9 February 2021. (klasener2021cd20asa pages 2-4, klasener2021cd20asa pages 1-2)
Rituximab exposure also rearranged receptors and transiently activated signaling in cultured human naïve B cells. In blood samples collected during rituximab administration to patients with rheumatoid arthritis, surface IgM initially rose, while CD19 rapidly decreased despite B cells still being detectable. With longer CD20 loss, Ramos cells showed a PAX5-to-BLIMP-1-associated change and plasma-cell-like characteristics. The latter fate experiment was largely in a lymphoma cell line, however, and should not be interpreted as showing that normal human B cells routinely become plasma cells after CD20 blockade. Kläsener et al., PNAS, 2021. (klasener2021cd20asa pages 4-5, klasener2021cd20asa pages 2-4, klasener2021cd20asa pages 1-2)
CD20 is thus connected to BCR–CD19–SYK–PI3K/AKT signaling and B-cell activation thresholds, rather than being established as a stand-alone receptor with a known extracellular ligand. Earlier human lymphoma-cell experiments also linked CD20 depletion to changes in BCR-associated LYN, SYK and ERK phosphorylation and BCR-triggered calcium signals; these findings establish pathway participation but do not by themselves identify a direct biochemical reaction performed by CD20. Pavlasova and Mraz, Haematologica, June 2020; Kläsener et al., PNAS, 2021. (pavlasova2020theregulationand pages 4-5, klasener2021cd20asa pages 1-2)
The evidence distinctions underlying this annotation are summarized here:
| Claim and evidence | Inference / uncertainty | Primary source (DOI; year) |
|---|---|---|
| Four-pass membrane dimer: Cryo-EM resolved human CD20 as two tightly associated four-transmembrane bundles forming a compact double-barrel dimer; the extracellular loops present paired antibody epitopes (rouge2020structureofcd20 pages 2-3, rouge2020structureofcd20 media 6925c4b6). | High-confidence structural evidence for purified, antibody-bound CD20. The oligomeric arrangement in an unliganded native B-cell membrane could be more dynamic. | Rougé et al., 10.1126/science.aaz9356; 2020 |
| Organizer of the resting B-cell surface: In human Ramos cells and primary naïve B cells, CD20 localized near the IgD-BCR/CD19 compartment. CRISPR loss reorganized IgM-BCR and CD19, increased SYK–AKT signaling and transient activation; conditional re-expression restored the resting phenotype (klasener2021cd20asa pages 1-2). | Strong mechanistic evidence, including loss and rescue. Ramos lymphoma cells are not fully equivalent to normal naïve B cells, but primary-cell and rituximab experiments support the membrane-nanodomain “gatekeeper” model. | Kläsener et al., 10.1073/pnas.2021342118; 2021 |
| Required for optimal humoral immunity: A patient with biallelic splice-disrupting MS4A1 variants had normal circulating B-cell numbers but markedly reduced class-switched memory B cells, low IgG and impaired pneumococcal-polysaccharide responses; anti-tetanus responses were preserved. Patient-derived cultured B-cell lines retained IgM/IgG-BCR-induced Ca²⁺ flux (kuijpers2010cd20deficiencyin pages 2-4, kuijpers2010cd20deficiencyin pages 4-5). | Direct human genetic evidence, but based on one exceptionally rare patient. It supports a nonredundant role in T-cell-independent antibody responses and shows that CD20 is not universally required for BCR-triggered Ca²⁺ mobilization. | Kuijpers et al., 10.1172/JCI40231; 2010 |
| Intrinsic Ca²⁺ channel activity is not established: Historical expression, silencing and crosslinking studies associated CD20 with Ca²⁺ conductance or BCR-linked Ca²⁺ flux (pavlasova2020theregulationand pages 4-5). However, the 3.3-Å structure showed a tightly sealed monomeric bundle and dimer interface with no plausible ion-permeation pathway (rouge2020structureofcd20 pages 2-3, rouge2020structureofcd20 pages 4-5). | Best current interpretation: CD20 regulates Ca²⁺ signaling indirectly through BCR organization or a larger channel/signaling complex rather than acting as a demonstrated pore. Definitive native-membrane electrophysiology and identification of partner channels remain needed. | Rougé et al., 10.1126/science.aaz9356; 2020; Pavlasova & Mraz, 10.3324/haematol.2019.243543; 2020 |
| Expression extends to a small human T-cell subset: Human CD20-negative T cells acquired CD20 and other B-cell proteins through trogocytosis, but circulating and CSF CD20⁺ T cells lacked those co-transferred markers. Naïve CD20⁺ T cells contained MS4A1 mRNA, and FOXO1 inhibition increased CD20, supporting endogenous expression in at least some cells (essen2024theoriginof pages 1-2, essen2024theoriginof pages 3-6). | Moderate evidence from small donor cohorts. Human CD20⁺ T cells may arise through both endogenous synthesis and transfer; their CD20-specific molecular function remains unresolved. Murine olfactory or T-cell findings should not be generalized to human MS4A1 without direct evidence. | von Essen et al., 10.3389/fimmu.2024.1487530; 2024 |
| Experimental restoration of target abundance: Salinomycin and monensin increased surface CD20 by 2.2–4-fold in human Raji cells at subtoxic concentrations and increased CD20 in primary CLL (salinomycin, n=24; monensin, n=13) and DLBCL samples (n=10) ex vivo. They enhanced rituximab, ofatumumab and CD20-CAR-T activity in experimental systems; benefit in mice was lost after MS4A1 disruption (torun2024potassiumsodiumcationcarriers pages 7-10). | Promising preclinical evidence only: effects involve MYC-dependent MS4A1 regulation and broader surface-protein changes, not selective CD20 modulation. Clinical efficacy and safety have not been demonstrated. | Torun et al., 10.3324/haematol.2024.285826; published online 2024 |
Table: Evidence-weighted summary of human MS4A1/CD20 structure, membrane-organizing function, calcium-signaling controversy, genetic deficiency, cellular expression and experimental target modulation.
Older overexpression, knockdown and antibody-crosslinking experiments suggested that CD20 participates in calcium conductance or calcium mobilization. A December 2024 MS4A-family review describes CD20 as an ion channel, but this is an interpretation of earlier functional assays, not direct identification of an ion-permeation pathway in human CD20. Conversely, the 2020 structure shows a sealed monomeric four-helix bundle and a closely packed dimer interface, and the authors conclude that neither provides a plausible ion-permeation route. Luo et al., Frontiers in Immunology, 9 December 2024; Rougé et al., Science, 2020. (luo2024ms4asuperfamilymolecules pages 2-3, rouge2020structureofcd20 pages 1-2, rouge2020structureofcd20 pages 3-4, rouge2020structureofcd20 pages 2-3, rouge2020structureofcd20 pages 4-5)
The human genetic counterexample is especially informative: B-cell lines made from a patient without surface CD20 still generated intracellular calcium flux after IgM- or IgG-BCR crosslinking. Other cell-line and mouse studies report reduced calcium responses after CD20 depletion. The defensible annotation is therefore modulator of BCR-associated calcium signaling, mechanism unresolved—not a confirmed Ca²⁺ transporter with a defined substrate-transport reaction. Kuijpers et al., Journal of Clinical Investigation, January 2010; Pavlasova and Mraz, Haematologica, June 2020. (kuijpers2010cd20deficiencyin pages 2-4, kuijpers2010cd20deficiencyin pages 4-5, pavlasova2020theregulationand pages 4-5)
A patient with biallelic MS4A1 splice-disrupting variants lacked detectable surface CD20 yet retained normal numbers of circulating B cells. The patient had low IgG and very few class-switched memory B cells (<2%, compared with a mean of 7.1% in the cited age-matched group), and showed impaired responses to pneumococcal polysaccharides but preserved anti-tetanus-toxoid IgG after boosters. Patient B cells proliferated to tested stimuli but produced little IgG in vitro. This identifies a nonredundant role in effective humoral immunity, particularly T-cell-independent polysaccharide antibody responses, without establishing that CD20 is essential for initial B-cell production. CD20-deficient mouse immunization experiments corroborated impaired T-independent responses, although model-dependent differences in T-dependent responses have also been reported. The human inference is limited by the exceptional rarity of genetically confirmed deficiency. Kuijpers et al., Journal of Clinical Investigation, January 2010; Pavlasova and Mraz, Haematologica, June 2020. (kuijpers2010cd20deficiencyin pages 1-2, kuijpers2010cd20deficiencyin pages 2-4, kuijpers2010cd20deficiencyin pages 4-5, pavlasova2020theregulationand pages 2-4)
Additional human evidence relates IgD to CD20-containing membrane organization: a 2023 study of eight people from three families with heterozygous IGHD variants found that IgD-negative naïve B cells expressed less CD20, CD19 and CD21 and responded less well to several tested stimuli. Because the causal perturbation was IGHD, not MS4A1, this supports coupling between IgD-associated B-cell state and CD20 abundance; it does not independently prove that CD20 caused those differences. Dirks et al., Frontiers in Immunology, 26 January 2023. (dirks2023igdshapesthe pages 1-2)
CD20 is not absolutely B-cell-exclusive. A November 2024 study reported CD20 on approximately 3–5% of circulating human T cells and distinguished two possible origins: transfer of CD20-containing membrane from B cells (trogocytosis) and endogenous expression. T cells acquired CD20 plus other B-cell markers during experimental coculture, but naturally occurring human CD20-positive T cells in blood and cerebrospinal fluid lacked those accompanying markers; sorted CD20-positive T cells contained MS4A1 RNA. These results support endogenous production in at least some human T cells, while leaving CD20’s specific signaling function there unresolved. von Essen et al., Frontiers in Immunology, 22 November 2024. (essen2024theoriginof pages 1-2, essen2024theoriginof pages 3-6)
A 2024 report also describes CD20-dependent predator-odor sensing in mouse olfactory neurons. That is not evidence that human MS4A1/P11836 serves as an olfactory receptor, and it should not displace the experimentally supported human B-cell annotation. Jiang et al., Nature Communications, April 2024; Luo et al., Frontiers in Immunology, 2024. (luo2024ms4asuperfamilymolecules pages 2-3)
CD20 is an accessible cell-surface target, not necessarily the direct signaling mechanism that makes its therapies effective. In B-cell malignancies, rituximab and other anti-CD20 antibodies deplete CD20-bearing cells through combinations of complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity and phagocytosis, and, for some antibodies or settings, direct cell death. Rituximab is used in B-cell lymphoma regimens; obinutuzumab and ofatumumab differ in epitope and effector profile. More recently, CD20×CD3 bispecific antibodies recruit T cells against malignant B cells; CD20-directed CAR T cells remain an investigational approach in the 2024 review. CD20 on mature B cells but usually not long-lived plasma cells also helps explain why depletion need not directly eliminate existing antibody-producing plasma cells. Dabkowska et al., Frontiers in Immunology, 4 April 2024; Rougé et al., Science, 2020. (dabkowska2024advancementsincancer pages 1-2, dabkowska2024advancementsincancer pages 5-6, dabkowska2024advancementsincancer pages 6-8, dabkowska2024advancementsincancer pages 8-9, rouge2020structureofcd20 pages 1-2)
Anti-CD20-mediated B-cell depletion is also used in multiple sclerosis. In the 2023 ALITHIOS ofatumumab extension report, the efficacy-analysis population comprised 1,882 people; the continuously treated group had an annualized relapse rate of approximately 0.05 over the reported follow-up, and 78.8% met the reported no-evidence-of-disease-activity criteria during the extension period. These are extension-study estimates, not evidence that one anti-CD20 agent outperforms all others. Indeed, a December 2024 network meta-analysis of 15 randomized trials found no statistically significant difference in annualized relapse rates between ublituximab and the other monoclonal antibodies it compared; indirect comparisons have their own limitations. Hauser et al., Multiple Sclerosis Journal, September 2023; Moloney et al., Frontiers in Neurology, 6 December 2024. (hauser2023efficacyandsafety pages 1-3, hauser2023efficacyandsafety pages 5-7, moloney2024comparativeefficacyand pages 1-2)
Antigen abundance and resistance are active research areas. CD20 loss or altered epitope expression can compromise antibody-based targeting, while other resistance mechanisms also exist; the accessible material for a February 2024 mosunetuzumab study included its experimental supplement rather than the full main results, so a precise incidence of CD20-negative relapse is not asserted here. In a separate study published online in 2024, salinomycin or monensin increased surface CD20 2.2–4-fold in Raji cells, with upregulation also tested in primary CLL samples (n=24 for salinomycin; n=13 for monensin) and DLBCL samples (n=10 for salinomycin). The agents increased anti-CD20 activity in experimental systems, but affected other surface proteins too; this is preclinical target-modulation research, not an established patient treatment. Schuster et al., Blood, February 2024; Torun et al., Haematologica, published online December 2024; Dabkowska et al., Frontiers in Immunology, 2024. (schuster2024lossofcd20 pages 1-7, schuster2024lossofcd20 pages 7-19, torun2024potassiumsodiumcationcarriers pages 7-10, dabkowska2024advancementsincancer pages 5-6)
Functional-annotation judgment: annotate human MS4A1/CD20 as a B-cell plasma-membrane, four-pass MS4A protein organizing IgD-associated receptor nanodomains and modulating BCR/CD19 activation, with a demonstrated contribution to optimal antibody responses. Record calcium signaling as associated but do not assign a definitive calcium-channel pore, transported substrate, enzyme activity, or human olfactory-receptor function on the present evidence. Kläsener et al., PNAS, 2021; Kuijpers et al., Journal of Clinical Investigation, 2010; Rougé et al., Science, 2020. (klasener2021cd20asa pages 1-2, kuijpers2010cd20deficiencyin pages 2-4, rouge2020structureofcd20 pages 4-5)
References
(pavlasova2020theregulationand pages 2-4): Gabriela Pavlasova and Marek Mraz. The regulation and function of cd20: an “enigma” of b-cell biology and targeted therapy. Haematologica, 105:1494-1506, Jun 2020. URL: https://doi.org/10.3324/haematol.2019.243543, doi:10.3324/haematol.2019.243543. This article has 591 citations.
(klasener2021cd20asa pages 1-2): Kathrin Kläsener, Julia Jellusova, Geoffroy Andrieux, Ulrich Salzer, Chiara Böhler, Sebastian N. Steiner, Jonas B. Albinus, Marco Cavallari, Beatrix Süß, Reinhard E. Voll, Melanie Boerries, Bernd Wollscheid, and Michael Reth. Cd20 as a gatekeeper of the resting state of human b cells. Proceedings of the National Academy of Sciences, Feb 2021. URL: https://doi.org/10.1073/pnas.2021342118, doi:10.1073/pnas.2021342118. This article has 149 citations and is from a highest quality peer-reviewed journal.
(rouge2020structureofcd20 pages 1-2): Lionel Rougé, Nancy Chiang, Micah Steffek, Christine Kugel, Tristan I. Croll, Christine Tam, Alberto Estevez, Christopher P. Arthur, Christopher M. Koth, Claudio Ciferri, Edward Kraft, Jian Payandeh, Gerald Nakamura, James T. Koerber, and Alexis Rohou. Structure of cd20 in complex with the therapeutic monoclonal antibody rituximab. Science, 367:1224-1230, Mar 2020. URL: https://doi.org/10.1126/science.aaz9356, doi:10.1126/science.aaz9356. This article has 245 citations and is from a highest quality peer-reviewed journal.
(rouge2020structureofcd20 pages 4-5): Lionel Rougé, Nancy Chiang, Micah Steffek, Christine Kugel, Tristan I. Croll, Christine Tam, Alberto Estevez, Christopher P. Arthur, Christopher M. Koth, Claudio Ciferri, Edward Kraft, Jian Payandeh, Gerald Nakamura, James T. Koerber, and Alexis Rohou. Structure of cd20 in complex with the therapeutic monoclonal antibody rituximab. Science, 367:1224-1230, Mar 2020. URL: https://doi.org/10.1126/science.aaz9356, doi:10.1126/science.aaz9356. This article has 245 citations and is from a highest quality peer-reviewed journal.
(rouge2020structureofcd20 pages 2-3): Lionel Rougé, Nancy Chiang, Micah Steffek, Christine Kugel, Tristan I. Croll, Christine Tam, Alberto Estevez, Christopher P. Arthur, Christopher M. Koth, Claudio Ciferri, Edward Kraft, Jian Payandeh, Gerald Nakamura, James T. Koerber, and Alexis Rohou. Structure of cd20 in complex with the therapeutic monoclonal antibody rituximab. Science, 367:1224-1230, Mar 2020. URL: https://doi.org/10.1126/science.aaz9356, doi:10.1126/science.aaz9356. This article has 245 citations and is from a highest quality peer-reviewed journal.
(rouge2020structureofcd20 media 6925c4b6): Lionel Rougé, Nancy Chiang, Micah Steffek, Christine Kugel, Tristan I. Croll, Christine Tam, Alberto Estevez, Christopher P. Arthur, Christopher M. Koth, Claudio Ciferri, Edward Kraft, Jian Payandeh, Gerald Nakamura, James T. Koerber, and Alexis Rohou. Structure of cd20 in complex with the therapeutic monoclonal antibody rituximab. Science, 367:1224-1230, Mar 2020. URL: https://doi.org/10.1126/science.aaz9356, doi:10.1126/science.aaz9356. This article has 245 citations and is from a highest quality peer-reviewed journal.
(klasener2021cd20asa pages 2-4): Kathrin Kläsener, Julia Jellusova, Geoffroy Andrieux, Ulrich Salzer, Chiara Böhler, Sebastian N. Steiner, Jonas B. Albinus, Marco Cavallari, Beatrix Süß, Reinhard E. Voll, Melanie Boerries, Bernd Wollscheid, and Michael Reth. Cd20 as a gatekeeper of the resting state of human b cells. Proceedings of the National Academy of Sciences, Feb 2021. URL: https://doi.org/10.1073/pnas.2021342118, doi:10.1073/pnas.2021342118. This article has 149 citations and is from a highest quality peer-reviewed journal.
(klasener2021cd20asa pages 4-5): Kathrin Kläsener, Julia Jellusova, Geoffroy Andrieux, Ulrich Salzer, Chiara Böhler, Sebastian N. Steiner, Jonas B. Albinus, Marco Cavallari, Beatrix Süß, Reinhard E. Voll, Melanie Boerries, Bernd Wollscheid, and Michael Reth. Cd20 as a gatekeeper of the resting state of human b cells. Proceedings of the National Academy of Sciences, Feb 2021. URL: https://doi.org/10.1073/pnas.2021342118, doi:10.1073/pnas.2021342118. This article has 149 citations and is from a highest quality peer-reviewed journal.
(pavlasova2020theregulationand pages 4-5): Gabriela Pavlasova and Marek Mraz. The regulation and function of cd20: an “enigma” of b-cell biology and targeted therapy. Haematologica, 105:1494-1506, Jun 2020. URL: https://doi.org/10.3324/haematol.2019.243543, doi:10.3324/haematol.2019.243543. This article has 591 citations.
(kuijpers2010cd20deficiencyin pages 2-4): Taco W. Kuijpers, Richard J. Bende, Paul A. Baars, Annette Grummels, Ingrid A.M. Derks, Koert M. Dolman, Tim Beaumont, Thomas F. Tedder, Carel J.M. van Noesel, Eric Eldering, and René A.W. van Lier. Cd20 deficiency in humans results in impaired t cell-independent antibody responses. The Journal of clinical investigation, 120 1:214-22, Jan 2010. URL: https://doi.org/10.1172/jci40231, doi:10.1172/jci40231. This article has 542 citations.
(kuijpers2010cd20deficiencyin pages 4-5): Taco W. Kuijpers, Richard J. Bende, Paul A. Baars, Annette Grummels, Ingrid A.M. Derks, Koert M. Dolman, Tim Beaumont, Thomas F. Tedder, Carel J.M. van Noesel, Eric Eldering, and René A.W. van Lier. Cd20 deficiency in humans results in impaired t cell-independent antibody responses. The Journal of clinical investigation, 120 1:214-22, Jan 2010. URL: https://doi.org/10.1172/jci40231, doi:10.1172/jci40231. This article has 542 citations.
(essen2024theoriginof pages 1-2): Marina Rode von Essen, Lisbeth Egelykke Stolpe, Helle Bach Søndergaard, and Finn Sellebjerg. The origin of human cd20+ t cells: a stolen identity? Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1487530, doi:10.3389/fimmu.2024.1487530. This article has 5 citations and is from a peer-reviewed journal.
(essen2024theoriginof pages 3-6): Marina Rode von Essen, Lisbeth Egelykke Stolpe, Helle Bach Søndergaard, and Finn Sellebjerg. The origin of human cd20+ t cells: a stolen identity? Frontiers in Immunology, Nov 2024. URL: https://doi.org/10.3389/fimmu.2024.1487530, doi:10.3389/fimmu.2024.1487530. This article has 5 citations and is from a peer-reviewed journal.
(torun2024potassiumsodiumcationcarriers pages 7-10): Anna Torun, Aleksandra Zdanowicz, Nina Miazek-Zapala, Piotr Zapala, Bhaskar Pradhan, Marta Jedrzejczyk, Andrzej Ciechanowicz, Zofia Pilch, Marcin Skorzynski, Mikołaj Słabicki, Grzegorz Rymkiewicz, Joanna Barankiewicz, Claudio Martines, Luca Laurenti, Marta Struga, Magdalena Winiarska, Jakub Golab, Magdalena Kucia, Mariusz Z. Ratajczak, Adam Huczynski, Dinis P. Calado, Dimitar G. Efremov, Abdessamad Zerrouqi, and Beata Pyrzynska. Potassium/sodium cation carriers robustly upregulate cd20 antigen by targeting myc, and synergize with anti- cd20 immunotherapies to eliminate malignant b cells. Haematologica, 110(7):1555-1572, Dec 2024. URL: https://doi.org/10.3324/haematol.2024.285826, doi:10.3324/haematol.2024.285826. This article has 6 citations.
(luo2024ms4asuperfamilymolecules pages 2-3): Xuejiao Luo, Bin Luo, Lei Fei, Qinggao Zhang, Xinyu Liang, Yongwen Chen, and Xueqin Zhou. Ms4a superfamily molecules in tumors, alzheimer’s and autoimmune diseases. Frontiers in Immunology, Dec 2024. URL: https://doi.org/10.3389/fimmu.2024.1481494, doi:10.3389/fimmu.2024.1481494. This article has 21 citations and is from a peer-reviewed journal.
(rouge2020structureofcd20 pages 3-4): Lionel Rougé, Nancy Chiang, Micah Steffek, Christine Kugel, Tristan I. Croll, Christine Tam, Alberto Estevez, Christopher P. Arthur, Christopher M. Koth, Claudio Ciferri, Edward Kraft, Jian Payandeh, Gerald Nakamura, James T. Koerber, and Alexis Rohou. Structure of cd20 in complex with the therapeutic monoclonal antibody rituximab. Science, 367:1224-1230, Mar 2020. URL: https://doi.org/10.1126/science.aaz9356, doi:10.1126/science.aaz9356. This article has 245 citations and is from a highest quality peer-reviewed journal.
(kuijpers2010cd20deficiencyin pages 1-2): Taco W. Kuijpers, Richard J. Bende, Paul A. Baars, Annette Grummels, Ingrid A.M. Derks, Koert M. Dolman, Tim Beaumont, Thomas F. Tedder, Carel J.M. van Noesel, Eric Eldering, and René A.W. van Lier. Cd20 deficiency in humans results in impaired t cell-independent antibody responses. The Journal of clinical investigation, 120 1:214-22, Jan 2010. URL: https://doi.org/10.1172/jci40231, doi:10.1172/jci40231. This article has 542 citations.
(dirks2023igdshapesthe pages 1-2): Johannes Dirks, Oliver Andres, Luisa Paul, Georgi Manukjan, Harald Schulze, and Henner Morbach. Igd shapes the pre-immune naïve b cell compartment in humans. Frontiers in Immunology, Jan 2023. URL: https://doi.org/10.3389/fimmu.2023.1096019, doi:10.3389/fimmu.2023.1096019. This article has 28 citations and is from a peer-reviewed journal.
(dabkowska2024advancementsincancer pages 1-2): Agnieszka Dabkowska, Krzysztof Domka, and Malgorzata Firczuk. Advancements in cancer immunotherapies targeting cd20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified t cells. Frontiers in Immunology, Apr 2024. URL: https://doi.org/10.3389/fimmu.2024.1363102, doi:10.3389/fimmu.2024.1363102. This article has 64 citations and is from a peer-reviewed journal.
(dabkowska2024advancementsincancer pages 5-6): Agnieszka Dabkowska, Krzysztof Domka, and Malgorzata Firczuk. Advancements in cancer immunotherapies targeting cd20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified t cells. Frontiers in Immunology, Apr 2024. URL: https://doi.org/10.3389/fimmu.2024.1363102, doi:10.3389/fimmu.2024.1363102. This article has 64 citations and is from a peer-reviewed journal.
(dabkowska2024advancementsincancer pages 6-8): Agnieszka Dabkowska, Krzysztof Domka, and Malgorzata Firczuk. Advancements in cancer immunotherapies targeting cd20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified t cells. Frontiers in Immunology, Apr 2024. URL: https://doi.org/10.3389/fimmu.2024.1363102, doi:10.3389/fimmu.2024.1363102. This article has 64 citations and is from a peer-reviewed journal.
(dabkowska2024advancementsincancer pages 8-9): Agnieszka Dabkowska, Krzysztof Domka, and Malgorzata Firczuk. Advancements in cancer immunotherapies targeting cd20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified t cells. Frontiers in Immunology, Apr 2024. URL: https://doi.org/10.3389/fimmu.2024.1363102, doi:10.3389/fimmu.2024.1363102. This article has 64 citations and is from a peer-reviewed journal.
(hauser2023efficacyandsafety pages 1-3): Stephen L Hauser, Ronald Zielman, Ayan Das Gupta, Jing Xi, Dee Stoneman, Goeril Karlsson, Derrick Robertson, Jeffrey A Cohen, and Ludwig Kappos. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the alithios open-label extension. Multiple Sclerosis (Houndmills, Basingstoke, England), 29:1452-1464, Sep 2023. URL: https://doi.org/10.1177/13524585231195346, doi:10.1177/13524585231195346. This article has 76 citations.
(hauser2023efficacyandsafety pages 5-7): Stephen L Hauser, Ronald Zielman, Ayan Das Gupta, Jing Xi, Dee Stoneman, Goeril Karlsson, Derrick Robertson, Jeffrey A Cohen, and Ludwig Kappos. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the alithios open-label extension. Multiple Sclerosis (Houndmills, Basingstoke, England), 29:1452-1464, Sep 2023. URL: https://doi.org/10.1177/13524585231195346, doi:10.1177/13524585231195346. This article has 76 citations.
(moloney2024comparativeefficacyand pages 1-2): Eoin Moloney, Atefeh Mashayekhi, Sakshi Sharma, Vasileios Kontogiannis, Amir Ansaripour, Wallace Brownlee, David Paling, and Mehdi Javanbakht. Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials. Frontiers in Neurology, Dec 2024. URL: https://doi.org/10.3389/fneur.2024.1479476, doi:10.3389/fneur.2024.1479476. This article has 11 citations and is from a peer-reviewed journal.
(schuster2024lossofcd20 pages 1-7): Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, and Elicia Penuel. Loss of cd20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory b-cell lymphomas. Feb 2024. URL: https://doi.org/10.1182/blood.2023022348, doi:10.1182/blood.2023022348. This article has 104 citations and is from a highest quality peer-reviewed journal.
(schuster2024lossofcd20 pages 7-19): Stephen J. Schuster, Ling-Yuh Huw, Christopher R. Bolen, Victor Maximov, Andrew G. Polson, Katerina Hatzi, Elisabeth A. Lasater, Sarit E. Assouline, Nancy L. Bartlett, L. Elizabeth Budde, Matthew J. Matasar, Hartmut Koeppen, Emily C. Piccione, Deanna Wilson, Michael C. Wei, Shen Yin, and Elicia Penuel. Loss of cd20 expression as a mechanism of resistance to mosunetuzumab in relapsed/refractory b-cell lymphomas. Feb 2024. URL: https://doi.org/10.1182/blood.2023022348, doi:10.1182/blood.2023022348. This article has 104 citations and is from a highest quality peer-reviewed journal.